行情

VVUS

VVUS

VIVUS
NASDAQ

实时行情|Nasdaq Last Sale

2.410
-0.140
-5.49%
盘后: 2.400 -0.01 -0.41% 19:58 02/20 EST
开盘
2.570
昨收
2.550
最高
2.588
最低
2.407
成交量
17.79万
成交额
--
52周最高
5.78
52周最低
2.100
市值
2,564.89万
市盈率(TTM)
-0.8705
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VVUS 新闻

  • Vivus up 4% premarket on Qsymia launch in Korea
  • seekingalpha.1天前
  • TSLA, PLUG among premarket gainers
  • Seeking Alpha - Article.1天前
  • VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream
  • GlobeNewswire.1天前
  • VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020
  • GlobeNewswire.2天前

更多

所属板块

制药
-0.54%
制药与医学研究
-0.40%

热门股票

名称
价格
涨跌幅

VVUS 简况

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
展开

Webull提供VIVUS, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。